Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Reprieve Cardiovascular
AddedFeb 15, 2024
UpdatedJun 18, 2026
Reprieve Cardiovascular

Reprieve Cardiovascular

Series A

Reprieve Cardiovascular: A medical device company dedicated to enhancing outcomes for acute heart failure patients.

HQ
Milford, MA, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Reprieve Cardiovascular, founded with a mission to improve outcomes for patients suffering from acute decompensated heart failure, is a medical device company that offers innovative solutions for heart failure management. The company's core product, the Reprieve System, is a personalized intelligent decongestion management (IDM) solution designed to enhance fluid management in heart failure patients. Reprieve Cardiovascular aims to address the prevalent and costly issue of heart failure, which affects millions of patients annually in the U.S.

Notable affiliated individuals and investors include experienced professionals in the medical device and cardiovascular fields. The company has achieved significant milestones, including the successful development and clinical trials of the Reprieve System. Reprieve Cardiovascular's impact lies in its potential to revolutionize heart failure treatment, offering a more effective and personalized approach to managing this chronic condition, thereby improving patient outcomes and reducing healthcare costs.

Reprieve Cardiovascular - Quick Facts

When was Reprieve Cardiovascular founded?

Reprieve Cardiovascular was founded in 2018.

Where is Reprieve Cardiovascular's headquarters located?

Reprieve Cardiovascular's headquarters is located in Milford, MA, US.

When was Reprieve Cardiovascular's last funding round?

Reprieve Cardiovascular's most recent funding round was for $12.1M (USD) in November 2023.

How much has Reprieve Cardiovascular raised to-date?

As of Nov 17, 2023, Reprieve Cardiovascular has raised a total of $49.1M (USD).

How many employees does Reprieve Cardiovascular have?

Reprieve Cardiovascular has 17 employees as of Feb 5, 2024.

Reprieve Cardiovascular - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 330000Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies